Literature DB >> 2831637

The effect of molecular weight on the bioavailability of heparin.

R M Emanuele1, J Fareed.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2831637     DOI： 10.1016/0049-3848(87)90391-4

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  7 in total

Review 1.  Clinical pharmacokinetics of epoetin (recombinant human erythropoietin).

Authors:  I C Macdougall; D E Roberts; G A Coles; J D Williams
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 2.  Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors:  D M Lutomski; M Bottorff; K Sangha
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

3.  Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study. Fraxiparin Anticoagulant Therapy in Myocardial Infarction Study Amsterdam (FATIMA) Study Group.

Authors:  S A Chamuleau; R J de Winter; M Levi; R Adams; H R Büller; M H Prins; K I Lie; R J Peters
Journal:  Heart       Date:  1998-07       Impact factor: 5.994

Review 4.  Heparin pharmacokinetics and pharmacodynamics.

Authors:  R J Kandrotas
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 5.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

6.  Natural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin.

Authors:  Se Jin Im; Sang In Yang; Se Hwan Yang; Dong Hoon Choi; So Young Choi; Hea Sook Kim; Do Soo Jang; Kyeong Sik Jin; Yo-Kyung Chung; Seung-Hee Kim; Sang Hoon Paik; Yoo Chang Park; Moon Koo Chung; Yong Bum Kim; Kang-Hyun Han; Kwan Yong Choi; Young Chul Sung
Journal:  PLoS One       Date:  2011-09-16       Impact factor: 3.240

7.  Innovative Three-Step Microwave-Promoted Synthesis of N-Propargyltetrahydroquinoline and 1,2,3-Triazole Derivatives as a Potential Factor Xa (FXa) Inhibitors: Drug Design, Synthesis, and Biological Evaluation.

Authors:  Fabián Santana-Romo; Carlos F Lagos; Yorley Duarte; Francisco Castillo; Yanina Moglie; Miguel A Maestro; Nitin Charbe; Flavia C Zacconi
Journal:  Molecules       Date:  2020-01-23       Impact factor: 4.411
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.